Table 2.
Treatments and clinical outcomes in COVID-19 and M. pneumoniae co-infection patients.
| Treatments and outcomes | COVID-19 mono-infection patients (n = 88) | COVID-19 patients co-infection with M. pneumoniae (n = 22) | p |
|---|---|---|---|
| Treatments | |||
| Antivirals | |||
| Umifenovir | 74 (84.1) | 16 (72.7) | 0.354 |
| Ribavirin | 58 (65.9) | 18 (81.8) | 0.235 |
| Interferon alpha inhalation | 1 (1.1) | 0 (0.0) | 1.000 |
| Lopinaviritonavir | 2 (2.3) | 1 (4.5) | 1.000 |
| Oseltamivir | 11 (12.5) | 4 (18.2) | 0.728 |
| Antibiotics | 24 (85.7%) | 47 (87%) | |
| Fluoroquinolones | 31 (35.2) | 18 (81.8) | <0.001 |
| Cephalosporins | 23 (26.1) | 11 (50.0) | 0.056 |
| Amoxicillin and Clavulanate Potassium | 0 (0.0) | 3 (13.6) | 0.005 |
| Corticosteroids | 25 (28.4) | 14 (63.6) | 0.005 |
| Outcomes | |||
| Discharge | 86 (97.7) | 21 (95.5) | 1.000 |
| Death | 2 (2.3) | 1 (4.5) | .. |
| Length of cough | 16.25 (12.25–22.50) | 20.00 (12.00–25.75) | 0.043 |
| Length of hospital stay (days) | 16.00 (10.00–22.25) | 14.00 (7.25–18.25) | 0.145 |
| Severity of disease | |||
| Mild | 84 (95.5) | 21 (95.5) | 1.000 |
| Moderate | 4 (4.5) | 1 (4.5) | .. |